Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4705192 | 0.85 | NR1I2 (0.40) | NR1I2SCN1ASCN1BSCN5ASCN8A | |
| SCHEMBL4689678 | 0.81 | MEN1 (0.52) | TDP1GAAMEN1KMT2AL3MBTL1 | |
| SCHEMBL18195967 | 0.76 | MEN1 (0.49) | NR1I2SCN1ASCN1BSCN5ASCN8A | |
| SCHEMBL6203897 | 0.72 | TDP1 (0.50) | SRCTDP1ABL1BCRGAA | |
| SCHEMBL4705013 | 0.71 | MAPT (0.42) | TDP1GAAMEN1KMT2AL3MBTL1 | |
| SCHEMBL4705511 | 0.68 | GAA (0.49) | TDP1GAAMEN1KMT2AL3MBTL1 | |
| SCHEMBL4705214 | 0.68 | MAPT (0.41) | TDP1GAAMEN1KMT2AL3MBTL1 | |
| SCHEMBL29019896 | 0.67 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1KRASP2RX3 | |
| SCHEMBL9762861 | 0.66 | TDP1 (0.48) | TDP1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2521168 | 0.66 | PFKFB3 (0.48) | HTR2AP2RX3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560832-B1 | PYRIMIDO 4,5-D PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | claimed |
| US-7112676-B2 | Pyrimido compounds having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-09-26 | — | — | US | claimed |
| EP-1560832-A1 | PYRIMIDO 4,5-D PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-10 | — | — | EP | claimed |
| US-20050075272-A1 | Pyrimido compounds having antiproliferative activity | DERMATAKIS APOSTOLOS (US) | 2005-04-07 | — | — | US | claimed |
| WO-2004041822-A1 | PYRIMIDO[4,5-D]PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | claimed |
| EP-1560832-B1 | PYRIMIDO 4,5-D PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| EP-1560832-B1 | PYRIMIDO 4,5-D PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7112676-B2 | Pyrimido compounds having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1560832-A1 | PYRIMIDO 4,5-D PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-10 | — | — | EP | disclosed |
| US-20050075272-A1 | Pyrimido compounds having antiproliferative activity | DERMATAKIS APOSTOLOS (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004041822-A1 | PYRIMIDO[4,5-D]PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075272-A1 | Pyrimido compounds having antiproliferative activity | LCK, FGFR1, FYN | NR1I2 2578/4885SCN1A 4621/4885SCN1B 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.